{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:16:10Z","timestamp":1783692970054,"version":"3.55.0"},"reference-count":49,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.2217\/imt-2018-0178","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T07:42:14Z","timestamp":1554709334000},"page":"737-754","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":42,"title":["Comparison of Janus Kinase Inhibitors in the Treatment of Rheumatoid Arthritis: A Systemic Literature Review"],"prefix":"10.1080","volume":"11","author":[{"given":"Jehanya","family":"Jegatheeswaran","sequence":"first","affiliation":[{"name":"University of Western Ontario, Schulich School of Medicine &amp; Dentistry, Department of Medicine,\u00a0London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Turk","sequence":"additional","affiliation":[{"name":"University of Western Ontario, Schulich School of Medicine &amp; Dentistry, Department of Medicine,\u00a0London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E","family":"Pope","sequence":"additional","affiliation":[{"name":"University of Western Ontario, Schulich School of Medicine &amp; Dentistry, Department of Medicine,\u00a0London, ON, Canada"},{"name":"Professor of Medicine, Division of Rheumatology, St. Joseph\u2019s Health Care &amp; University of Western Ontario, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33383"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33419"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24567"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.995875"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37816"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00006"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310476"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31618-5"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3436-1"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-018-0531-5"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206478"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150613"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210094"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39953"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4221-0"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171361"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39801"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39808"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31115-2"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40186"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210104"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210105"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40054"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39955"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208279"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38949"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39473"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208901"},{"issue":"2","key":"e_1_3_2_37_1","first-page":"318","article-title":"The mechanism of action of tofacitinib \u2013 an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge JA","year":"2016","unstructured":"Hodge JA , KawabataTT , KrishnaswamiSet al. The mechanism of action of tofacitinib \u2013 an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin. Exp. Rheum.34(2), 318\u2013328 (2016).","journal-title":"Clin. Exp. Rheum."},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-9255-7-41"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.273"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0723-3"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211555"},{"key":"e_1_3_2_42_1","unstructured":"AbbVie Upadacitinib meets all primary and ranked secondary endpoints including superiority versus adalimumab in Phase III study in rheumatoid arthritis( 2018). https:\/\/news.abbvie.com\/news\/upadacitinib-meets-all-primary-and-ranked-secondary-endpoints-including-superiority-versus-adalimumab-in-phase-3-study-in-rheumatoid-arthritis.htm"},{"issue":"10","key":"e_1_3_2_43_1","article-title":"Safety and efficacy of filgotinib in a Phase III trial of patients with active rheumatoid arthritis and inadequate response or intolerance to biologic dmards [abstract]","volume":"70","author":"Genovese MC","year":"2018","unstructured":"Genovese MC , KalunianKC , WalkerD et al. Safety and efficacy of filgotinib in a Phase III trial of patients with active rheumatoid arthritis and inadequate response or intolerance to biologic dmards [abstract]. Arthritis Rheum.70(suppl. 10), (2018). https:\/\/acrabstracts.org\/abstract\/safety-and-efficacy-of-filgotinib-in-a-phase-3-trial-of-patients-with-active-rheumatoid-arthritis-and-inadequate-response-or-intolerance-to-biologic-dmards\/","journal-title":"Arthritis Rheum."},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.03.038"},{"issue":"9","key":"e_1_3_2_45_1","first-page":"1088","article-title":"An economic evaluation of tofacitinib treatment in rheumatoid arthritis: modeling the cost of treatment strategies in the United States","volume":"22","author":"Claxton L","year":"2016","unstructured":"Claxton L , JenksM , TaylorMet al. An economic evaluation of tofacitinib treatment in rheumatoid arthritis: modeling the cost of treatment strategies in the United States. J. Manag. Care Spec. Pharm.22(9), 1088\u20131102 (2016).","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"10","key":"e_1_3_2_46_1","article-title":"Persistence of tofacitinib in the treatment of rheumatoid arthritis in open-label, long-term extension studies up to 8years","volume":"68","author":"Pope J","year":"2016","unstructured":"Pope J , KeystoneE , JamalS et al. Persistence of tofacitinib in the treatment of rheumatoid arthritis in open-label, long-term extension studies up to 8years. Arthritis Rheum.68(suppl 10), (2016). https:\/\/acrabstracts.org\/abstract\/persistence-of-tofacitinib-in-the-treatment-of-rheumatoid-arthritis-in-open-label-long-term-extension-studies-up-to-8-years\/","journal-title":"Arthritis Rheum."},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210457"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214367"},{"issue":"10","key":"e_1_3_2_49_1","article-title":"Comparative risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors: a cohort study of rheumatoid arthritis patients [abstract]","volume":"70","author":"Desai RJ","year":"2018","unstructured":"Desai RJ , PawarA , WeinblattME , KimSC. Comparative risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors: a cohort study of rheumatoid arthritis patients [abstract]. Arthritis Rheum.70(suppl. 10), (2018).","journal-title":"Arthritis Rheum."},{"issue":"10","key":"e_1_3_2_50_1","article-title":"Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis [abstract]","volume":"70","author":"Genovese MC","year":"2018","unstructured":"Genovese MC , SmolenJS , TakeuchiT et al. Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis [abstract]. Arthritis Rheum.70(suppl. 10), (2018). https:\/\/acrabstracts.org\/abstract\/safety-profile-of-baricitinib-for-the-treatment-of-rheumatoid-arthritis-up-to-6-years-an-updated-integrated-safety-analysis\/","journal-title":"Arthritis Rheum."}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2018-0178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T12:59:33Z","timestamp":1715950773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2018-0178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.2217\/imt-2018-0178"],"URL":"https:\/\/doi.org\/10.2217\/imt-2018-0178","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-11-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}